Table 4.
Co-occurrence analysis of ERBB family and PIK3CA mutations in datasets where ERBB family mutations are enriched. Analysis was taken from www.cbioportal.org. Log odds ratio values increase as the likelihood of the co-occurrence increases.
| Study/cancer type | No. cases | Significant pair 1 (tendency towards co-occurrence) | p value | Log odds ratio | Significant pair 2 (tendency towards co-occurrence) | p value | Log odds ratio | Significant pair 3 (tendency towards co-occurrence) | p value | Log odds ratio |
|---|---|---|---|---|---|---|---|---|---|---|
| Bladder urothelial carcinoma | 130 | ERBB3 and PIK3CA | 0.035 | 1.281 | EGFR and PIK3CA | 0.039 | >3 | |||
| Cervical squamous cell carcinoma and endocervical adenocarcinoma | 194 | ERBB2 and PIK3CA | 0.027 | 1.475 | ||||||
| Colorectal adenocarcinoma | 619 | ERBB2 and PIK3CA | 0.02 | 0.833 | EGFR and PIK3CA | 0.034 | 0.86 | |||
| Esophageal carcinoma | 185 | |||||||||
| Head and neck squamous cell carcinoma | 279 | |||||||||
| Pan-lung cancer | 1144 | |||||||||
| Stomach adenocarcinoma | 289 | ERBB3 and PIK3CA | 0.008 | 1.095 | EGFR and PIK3CA | 0.014 | 1.366 | ERBB2 and PIK3CA | 0.037 | 1.192 |
| Skin cutaneous melanoma | 366 | |||||||||
| Uterine corpus endometrioid carcinoma | 248 | ERBB3 and PIK3CA | 0.011 | 1.497 |